AR111594A1 - Agentes inhibidores de la tirosina quinasa de bruton - Google Patents
Agentes inhibidores de la tirosina quinasa de brutonInfo
- Publication number
- AR111594A1 AR111594A1 ARP180100935A ARP180100935A AR111594A1 AR 111594 A1 AR111594 A1 AR 111594A1 AR P180100935 A ARP180100935 A AR P180100935A AR P180100935 A ARP180100935 A AR P180100935A AR 111594 A1 AR111594 A1 AR 111594A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered monocyclic
- alkynyl
- alkenyl
- carbocyclyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 11
- 125000005843 halogen group Chemical group 0.000 abstract 7
- -1 2 - ((1-methyl-1 H -pyrazol-4-yl) amino) pyrimidin-4-yl Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable, en donde: el anillo A es un heteroarilo monocíclico de 5 miembros que contiene 3 heteroátomos seleccionados independientemente entre N, O y S, en donde dicho heteroarilo monocíclico de 5 miembros está opcionalmente sustituido con uno o más R¹; Q¹, Q² y Q³ son cada uno, independientemente, seleccionados de O, N(R²) y CH-R³, en donde al menos dos de Q¹, Q² y Q³ son C-R³; W se selecciona de CH y N; Y se selecciona de CH y N; R¹ en cada caso se selecciona independientemente de alquilo C₁₋₆ y carbociclilo de 3 a 5 miembros, en donde dicho alquilo C₁₋₆ y carbociclilo de 3 a 5 miembros están opcionalmente sustituidos con uno o más R¹⁰; R¹⁰ en cada caso se selecciona independientemente de halo, -CN, alquilo C₁₋₆ y carbociclilo de 3 a 5 miembros; R² se selecciona de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, heterociclilo monocíclico de 4 a 6 miembros, -CN, -C(O)R²ᵃ, -C(O)₂R²ᵃ, -C(O)N(R²ᵃ)₂, -S(O)₂R²ᵃ, y -S(O)₂N(R²ᵃ)₂, en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, y heterociclilo monocíclico de 4 a 6 miembros están opcionalmente sustituidos con uno o más R²⁰; R²ᵃ en cada aparición se selecciona independientemente de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, y heterociclilo monocíclico de 4 a 6 miembros, en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, y heterociclilo monocíclico de 4 a 6 miembros en cada aparición están opcionalmente e independientemente sustituidos con uno o más R²⁰; R²⁰ en cada aparición se selecciona independientemente de alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, heterociclilo monocíclico de 4 a 6 miembros, halo, -CN, -C(O)R²⁰ᵃ, -C(O)₂R²⁰ᵃ, -C(O)N(R²⁰ᵃ)₂, -N(R²⁰ᵃ)₂, -N(R²⁰ᵃ)C(O)R²⁰ᵃ, -N(R²⁰ᵃ)C(O)₂R²⁰ᵃ, -N(R²⁰ᵃ)C(O)N(R²⁰ᵃ)₂, -N(R²⁰ᵃ)S(O)₂R²⁰ᵃ, -OR²⁰ᵃ, -OC(O)R²⁰ᵃ, -OC(O)N(R²⁰ᵃ)₂, -SR²⁰ᵃ, -S(O)R²⁰ᵃ, -S(O)₂R²⁰ᵃ, -S(O)N(R²⁰ᵃ)₂, y -S(O)₂N(R²⁰ᵃ)₂; R²⁰ᵃ en cada aparición se selecciona independientemente de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros y heterociclilo monocíclico de 4 a 6 miembros; R³ se selecciona de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, heterociclilo monocíclico de 4 a 6 miembros, halo, -CN, -C(O)R³ᵃ, -C(O)₂R³ᵃ, -C(O)N(R³ᵃ)₂, -N(R³ᵃ)₂, -N(R³ᵃ)C(O)R³ᵃ, -N(R³ᵃ)C(O)₂R³ᵃ, -N(R³ᵃ)C(O)N(R³ᵃ)₂, -N(R³ᵃ)S(O)₂R³ᵃ, -OR³ᵃ, -OC(O)R³ᵃ, -OC(O)N(R³ᵃ)₂, -SR³ᵃ, -S(O)R³ᵃ, -S(O)₂R³ᵃ, -S(O)N(R³ᵃ)₂, y -S(O)₂N(R³ᵃ)₂, en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, y heterociclilo monocíclico de 4 a 6 miembros están opcionalmente sustituidos con uno o más R³⁰; R³ᵃ en cada aparición se selecciona independientemente de H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros, y heterociclilo monocíclico de 4 a 6 miembros, en donde dicho alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros y heterociclilo monocíclico de 4 a 6 miembros en cada aparición están opcional e independientemente sustituidos con uno o más R³⁰; R³⁰ en cada aparición se selecciona independientemente de alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico de 4 a 6 miembros heterociclilo monocíclico de 4 a 6 miembros, halo, -CN, -C(O)R³⁰ᵃ, -C(O)₂R³⁰ᵃ, -C(O)N(R³⁰ᵃ)₂, -N(R³⁰ᵃ)₂, -N(R³⁰ᵃ)C(O)R³⁰ᵃ, -N(R³⁰ᵃ)C(O)₂R³⁰ᵃ, -N(R³⁰ᵃ)C(O)N(R³⁰ᵃ)₂, -N(R³⁰ᵃ)S(O)₂R³⁰ᵃ, -OR³⁰ᵃ, -OC(O)R³⁰ᵃ, -OC(O)N(R³⁰ᵃ)₂, -SR³⁰ᵃ, -S(O)R³⁰ᵃ, -S(O)₂R³⁰ᵃ, -S(O)N(R³⁰ᵃ)₂, y -S(O)₂N(R³⁰ᵃ)₂; R³⁰ᵃ en cada aparición se selecciona independientemente de; H, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, carbociclilo monocíclico do 4 a 6 miembros y heterociclilo monocíclico de 4 a 6 miembros; R⁴ se selecciona de H y alquilo C₁₋₆, en donde dicho alquilo C₁₋₆ está opcionalmente sustituido con uno o más halo; R⁵ se selecciona de H y alquilo C₁₋₆ en donde dicho alquilo C₁₋₆ está opcionalmente sustituido con uno o más halo; R⁶ se selecciona de H y alquilo C₁₋₆, en donde dicho alquilo C₁₋₆ está opcionalmente sustituido con uno o más halo; o R⁵ y R⁶, junto con los átomos a los que están unidos, forman un anillo que contiene uno o dos heteroátomos seleccionados de O, N y S, en donde el anillo está opcionalmente sustituido con uno o mas R⁵⁰; y R⁵⁰ es alquilo C₁₋₆. Reivindicación 38: La forma A cristalina de (R)-1-(terc-butil)-N-(8-(2-((1-metil-1H-pirazol-4-il)amino)pirimidin-4-il)-2-(oxetan-3-il)-2,3,4,5-tetrahidro-1H-benzo[c]azepin-5-il)-1H-1,2,3-triazol-4-carboxamida. Reivindicación 48: La forma G cristalina de (R)-1-(terc-butil)-N-(8-(2-((1-metil-1H-pirazol-4-il)amino)pirimidin-4-il)-2-(oxetan-3-il)-2,3,4,5-tetrahidro-1H-benzo[c]azepin-5-il)-1H-1,2,3-triazol-4-carboxamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485745P | 2017-04-14 | 2017-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111594A1 true AR111594A1 (es) | 2019-07-31 |
Family
ID=62092333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100935A AR111594A1 (es) | 2017-04-14 | 2018-04-13 | Agentes inhibidores de la tirosina quinasa de bruton |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US10227341B2 (es) |
| EP (2) | EP4249071A3 (es) |
| JP (2) | JP7145874B2 (es) |
| KR (2) | KR20230164247A (es) |
| CN (2) | CN117567453A (es) |
| AR (1) | AR111594A1 (es) |
| AU (3) | AU2018253209B2 (es) |
| BR (1) | BR112019021399A2 (es) |
| CA (1) | CA3058774A1 (es) |
| CL (1) | CL2019002900A1 (es) |
| CO (1) | CO2019012571A2 (es) |
| CR (1) | CR20190517A (es) |
| DK (1) | DK3609886T3 (es) |
| EA (1) | EA201992354A1 (es) |
| ES (1) | ES2975769T3 (es) |
| FI (1) | FI3609886T3 (es) |
| HR (1) | HRP20240361T1 (es) |
| HU (1) | HUE066253T2 (es) |
| IL (2) | IL269933B (es) |
| JO (1) | JOP20190233A1 (es) |
| LT (1) | LT3609886T (es) |
| MA (1) | MA50013B1 (es) |
| MD (1) | MD3609886T2 (es) |
| MX (1) | MX2023000812A (es) |
| PE (2) | PE20240930A1 (es) |
| PH (1) | PH12019502334A1 (es) |
| PL (1) | PL3609886T3 (es) |
| PT (1) | PT3609886T (es) |
| RS (1) | RS65386B1 (es) |
| SA (1) | SA519410292B1 (es) |
| SG (1) | SG11201909224QA (es) |
| SI (1) | SI3609886T1 (es) |
| TW (1) | TWI790227B (es) |
| UA (1) | UA127347C2 (es) |
| WO (1) | WO2018191577A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2932608C (en) | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| MA53914A (fr) * | 2018-10-15 | 2021-08-25 | Biogen Ma Inc | Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton |
| WO2020084978A1 (ja) | 2018-10-22 | 2020-04-30 | 株式会社村田製作所 | バルブ、及び、気体制御装置 |
| JP2022532235A (ja) * | 2019-05-15 | 2022-07-13 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023086521A1 (en) | 2021-11-10 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
| EP2209786B1 (en) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| US20110009421A1 (en) | 2008-02-27 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2727455C (en) | 2008-06-27 | 2019-02-12 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| NZ598985A (en) * | 2009-09-04 | 2013-07-26 | Biogen Idec Inc | Bruton's tyrosine kinase inhibitors |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| PT3689878T (pt) | 2011-07-19 | 2022-01-05 | Merck Sharp & Dohme | 4-imidazopiridazin-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk |
| TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
| ES2742305T3 (es) | 2013-10-21 | 2020-02-13 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de BTK y sus usos |
| CA2932608C (en) * | 2013-12-11 | 2023-02-14 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| KR102523111B1 (ko) * | 2014-10-06 | 2023-04-18 | 메르크 파텐트 게엠베하 | Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도 |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2017
- 2017-06-16 JO JOP/2019/0233A patent/JOP20190233A1/ar unknown
-
2018
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/en active Pending
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/en active Application Filing
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 KR KR1020237040706A patent/KR20230164247A/ko active Application Filing
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 IL IL294175A patent/IL294175A/en unknown
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/en active Active
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 CA CA3058774A patent/CA3058774A1/en active Pending
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active IP Right Grant
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 BR BR112019021399A patent/BR112019021399A2/pt active Search and Examination
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
-
2019
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
-
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
-
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP2022180498A/ja active Pending
-
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111594A1 (es) | Agentes inhibidores de la tirosina quinasa de bruton | |
| AR121016A2 (es) | Sales de fenotiazindiaminio y su uso | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR115949A1 (es) | Compuestos heterocíclicos | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| UY38296A (es) | Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR115085A1 (es) | DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk) | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| RS54180B1 (en) | FUSIONAL HETEROAROMATIC PYROLIDINONS AS SYK INHIBITORS | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |